Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

PURPOSE: Ki67 assessed at diagnosis (Ki67(baseline)) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki67(2week)) is associated with clinical benefit from endocrine therapies and residual Ki67 (Ki67(2week)) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bliss, Judith M., Tovey, Holly, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Mallon, Elizabeth, Vidya, Raghavan, Skene, Anthony, Dodson, Andrew, Hills, Margaret, Detre, Simone, Zabaglo, Lila, Banerji, Jane, Kilburn, Lucy, Morden, James P., Robertson, John F. R., Smith, Ian, Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099675/
https://www.ncbi.nlm.nih.gov/pubmed/37046348
http://dx.doi.org/10.1186/s13058-023-01626-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099675/
https://www.ncbi.nlm.nih.gov/pubmed/37046348
http://dx.doi.org/10.1186/s13058-023-01626-3

Ejemplares similares